content_image/142727.jpg content_image/142737.jpg
## Clinical Development: Bringing Innovative Therapeutics to Patients 

<img src='content_image/142727.jpg'>

In clinical development, we aim to maximize the potential of Astellas’ portfolio by extracting the full value from both pipeline medicines and approved products. We are focused on obtain- ing regulatory approvals with commercially desirable labels and bringing innovative medicines to patients. 

Currently, we have over 15 Phase 3 projects in the devel- opment pipeline, along with many unique projects at earlier stages. In fiscal 2013, we obtained regulatory approvals for 10 projects in Japan, the U.S. and Europe, including the 

## Status of R&D Pipeline 

Products approved in/after April 2013 

new molecular entities XTANDI and Suglat. We have main- tained this momentum in fiscal 2014, and these efforts are continuing to produce many successful results. Our com- petitive advantage in each therapeutic area and region is supported by the world class talent who are attracted to our organization. 

Looking ahead, we will continue to pursue development in line with our Global Category Leader (GCL) strategy. In the fields of urology, immunology and infectious diseases for example, we will seek to maximize the potential of our existing franchises, while expanding our focus to cover new and related diseases. In oncology, our goals are to establish a business platform with our cornerstone treatments, and to channel advances in research into expanding the patient population for those treatments and adding further indications. 

Through these efforts we will contribute even more to Astellas’ goal of delivering effective new drugs to patients as quickly as possible. 

(as of August 1, 2014) 

<img src='content_image/142737.jpg'>

*1 “In-house” shown in the “Origin” column includes discovery through collaborative research (same below). 

*2 Precautions regarding indication include the description that the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy. 

